Telix Pharmaceuticals Limited (TLX)
(Delayed Data from NSDQ)
$10.93 USD
+0.88 (8.76%)
Updated Sep 23, 2025 04:00 PM ET
After-Market: $10.92 -0.01 (-0.09%) 7:58 PM ET
4-Sell of 5 4
D Value C Growth F Momentum D VGM
Fundamental Charts
About Dividend Yield (TTM)
Telix Pharmaceuticals Limited's dividend yield currently sits at 0%, which is in-line with the Medical - Biomedical and Genetics industry's yield of 0.00%.
The company's trailing twelve month (TTM) Dividend Yield calculates the indicated annual dividend divided by the stock price. This value is always expressed as a percentage. This is the return on investment that is specifically attributed to the expected dividends that are paid out over a year. Note: investors should not base their investments on the size of the dividend yield alone. Seek attractive dividend yields, but only on top rated stocks with a solid payment history.
TLX 10.93 +0.88(8.76%)
Will TLX be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for TLX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for TLX
All You Need to Know About Telix Pharmaceuticals Limited (TLX) Rating Upgrade to Buy
Telix Shares May Gain on the Distribution Deal With Cardinal Health
TLX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Telix Pharmaceuticals Limited (TLX) Upgraded to Buy: What Does It Mean for the Stock?
What Makes Telix Pharmaceuticals Limited (TLX) a Good Fit for 'Trend Investing'
Other News for TLX
UBS Maintains Buy Rating on TLX, Lowers Target Price to $20 | TLX Stock News
Telix Pharmaceuticals price target lowered by $3 at UBS
Is TLX signaling a buying opportunity? Crossed Above 20 Day Moving Average shows up after rising 0.7%
UBS Sticks to Its Buy Rating for Telix Pharmaceuticals (TLPPF)
Telix Pharmaceuticals (TLPPF) Receives a Buy from Morgan Stanley